Annovis Bio plans public offering to fund development of lead compound Buntanetap

From GlobeNewswire: 2025-01-31 20:14:02

Annovis Bio, Inc. plans to offer common stock and warrants in a public offering to fund clinical development of their lead compound, Buntanetap. ThinkEquity will be the book-running manager. The Company will grant the underwriter a 45-day option to purchase up to an additional 15% of shares to cover over-allotments. The offering is subject to market conditions, and proceeds will primarily be used for working capital and general corporate purposes. Interested parties can access more information about the offering through the SEC website. Annovis Bio aims to address neurodegenerative diseases like Alzheimer’s and Parkinson’s through innovative therapies targeting multiple neurotoxic proteins.



Read more at GlobeNewswire: Annovis Bio, Inc. Announces Proposed Public Offering